Stoke Therapeutics posted Q2 net loss of USD 61.6 million, or USD 0.93 a share, widening from a USD 23.5 million loss.
Revenue fell 32.52% to USD 9.33 million; R&D expenses climbed 91.45% to USD 49.5 million.
SG&A costs increased 65.29% to USD 25.25 million, driven by growth in personnel and launch readiness expenses.
Cash position and program updates
Cash, cash equivalents and marketable securities totaled USD 420 million, expected to fund operations through potential U.S. commercialization in early 2028.
Phase 3 EMPEROR enrollment of 162 zorevunersen patients is complete; Phase 3 data are expected in Q3 2027, with rolling U.S. NDA start planned in Q1 2027.
STOK•
